

BEFORE THE  
INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE  
TO THE  
CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE  
ORGANIZED PURSUANT TO THE  
CALIFORNIA STEM CELL RESEARCH AND CURES ACT  
SPECIAL MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: TUESDAY, AUGUST 21, 2012  
4 P.M.

REPORTER: BETH C. DRAIN, CSR  
CSR. NO. 7152

BRS FILE NO.: 92824

## BARRISTERS' REPORTING SERVICE

### I N D E X

ITEM DESCRIPTION	PAGE NO.
1. CALL TO ORDER.	3
2. ROLL CALL.	3
3. CONSIDERATION OF EARLY TRANSLATIONAL IV CONCEPT PROPOSAL.	5
4. CONSIDERATION OF APPOINTMENT OF NEW SCIENTIFIC MEMBERS OF THE GRANTS WORKING GROUP	20

**BARRISTERS' REPORTING SERVICE**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

TUESDAY, AUGUST 21, 2012; 4 P.M.

CHAIRMAN THOMAS: CALL THE AUGUST 21, 2012, MEETING OF THE INDEPENDENT CITIZENS OVERSIGHT COMMITTEE TO ORDER. FIRST ORDER OF BUSINESS, ROLL CALL. MARIA, PLEASE CALL THE ROLL.

MS. BONNEVILLE: ROBERT PRICE.

DR. PRICE: HERE.

MS. BONNEVILLE: DAVID BRENNER. JACOB LEVIN. CLAIRE POMEROY.

DR. POMEROY: HERE.

MS. BONNEVILLE: MARCY FEIT. TED Krontiris.

DR. Krontiris: HERE.

MS. BONNEVILLE: LEEZA GIBBONS.

MS. GIBBONS: HERE.

MS. BONNEVILLE: MICHAEL GOLDBERG.

MR. GOLDBERG: HERE.

MS. BONNEVILLE: SAM HAWGOOD. STEPHEN JUELsgaard. SHERRY LANSING.

MS. LANSING: HERE.

MS. BONNEVILLE: BERT LUBIN. MICHAEL MARLETTA.

MS. BONNEVILLE: LEON FINE.

DR. FINE: HERE.

**BARRISTERS' REPORTING SERVICE**

1 MS. BONNEVILLE: PHIL PIZZO. FRANCISCO  
2 PRIETO.  
3 DR. PRIETO: HERE.  
4 MS. BONNEVILLE: CARMEN PULIAFITO. ROBERT  
5 QUINT.  
6 DR. QUINT: HERE.  
7 MS. BONNEVILLE: DUANE ROTH.  
8 MR. ROTH: HERE.  
9 MS. BONNEVILLE: JOAN SAMUELSON.  
10 MS. SAMUELSON: HERE.  
11 MS. BONNEVILLE: DAVID SERRANO-SEWELL.  
12 MR. SERRANO-SEWELL: HERE.  
13 MS. BONNEVILLE: JEFF SHEEHY.  
14 MR. SHEEHY: HERE.  
15 MS. BONNEVILLE: JONATHAN SHESTACK.  
16 MR. SHESTACK: HERE.  
17 MS. BONNEVILLE: OSWALD STEWARD.  
18 DR. STEWARD: HERE.  
19 MS. BONNEVILLE: JONATHAN THOMAS.  
20 CHAIRMAN THOMAS: HERE.  
21 MS. BONNEVILLE: ART TORRES.  
22 MR. TORRES: HERE.  
23 MS. BONNEVILLE: KRISTINA VUORI.  
24 DR. VUORI: HERE.  
25 MS. BONNEVILLE: JAMES ECONOMOU.

**BARRISTERS' REPORTING SERVICE**

1 DR. ECONOMOU: HERE.

2 MS. BONNEVILLE: DID SOMEONE JUST JOIN?

3 DR. FIRESTEIN: GARY FIRESTEIN.

4 MS. BONNEVILLE: THANK YOU.

5 CHAIRMAN THOMAS: WELCOME, GARY. J.T.

6 HERE. WE ARE NOW PROCEEDING TO ITEM 3 ON TODAY'S  
7 AGENDA, WHICH IS CONSIDERATION OF THE EARLY  
8 TRANSLATIONAL IV CONCEPT PROPOSAL. TURN IT OVER TO  
9 PAT AND LILA.

10 DR. OLSON: THANK YOU VERY MUCH, MR.  
11 CHAIRMAN, AND THANKS ALL, BOARD MEMBERS, FOR JOINING  
12 US FOR THIS AFTERNOON BOARD MEETING.

13 WHAT I'D LIKE TO DO FIRST IS I'D LIKE TO  
14 JUST DO A QUICK REVIEW OF WHERE WE ARE IN THE  
15 FINANCIAL RFA STRATEGIC PLAN. WHEN WE HAD THE  
16 DISCUSSION LAST MARCH, WE AGREED THAT EVERY TIME WE  
17 WANTED TO BRING FORTH A CONCEPT PROPOSAL, WE WOULD  
18 UPDATE YOU WITH RESPECT TO WHERE WE ARE ON OUR  
19 AWARDS, ON OUR CONCEPTS, AND ON OUR FUTURE FUNDING.

20 SO I BELIEVE YOU HAVE A SLIDE  
21 PRESENTATION, AND I JUST WANT TO TAKE A FEW MINUTES  
22 TO WALK THROUGH THAT PRIOR TO DR. LILA COLLINS  
23 PRESENTING THE PROPOSAL FOR THE CONCEPT PLAN FOR THE  
24 EARLY TRANSLATIONAL IV.

25 SO SINCE WE LAST PRESENTED THE COMPLETE

**BARRISTERS' REPORTING SERVICE**

1 FINANCIAL PLAN, WHICH WAS THEN INCORPORATED IN THE  
2 STRATEGIC PLAN THAT YOU APPROVED AT THE MAY BOARD  
3 MEETING, THE FOLLOWING ARE KEY CHANGES THAT HAVE  
4 OCCURRED. AND I'M ON SLIDE 2. ESSENTIALLY THE  
5 DISEASE TEAM THERAPY DEVELOPMENT AWARD, THE AWARDED  
6 SEGMENT OF THE GRAPHS OR THE TABLE NOW INCLUDES THE  
7 \$151 MILLION THAT WAS APPROVED FOR FUNDING BY THE  
8 BOARD AT YOUR LAST BOARD MEETING. AND THAT SIMILAR  
9 AMOUNT HAS BEEN TAKEN OUT OF THE CONCEPT APPROVED.

10 FUTURE AWARDS, ACTUALLY IN THE FUTURE  
11 AWARDS, UNALLOCATED NOW INCLUDES THE BALANCE OF THE  
12 240 MILLION, WHICH IS 89 MILLION, THAT WAS APPROVED  
13 FOR THE DT2 CONCEPT FOR WHICH YOU MAY -- AT THE  
14 UPCOMING MEETING, THAT MAY CHANGE, BUT AT THE MOMENT  
15 IT'S IN THE UNALLOCATED CATEGORY.

16 LEADERSHIP AWARDS, THE AWARDED CATEGORY  
17 NOW INCLUDES THE 5.6 MILLION THAT YOU APPROVED FOR  
18 FUNDING AT YOUR MAY BOARD MEETING. THAT WAS THE UC  
19 BERKELEY CANDIDATE. AND IT ALSO INCLUDES 12.4  
20 MILLION THAT ACTUALLY IS RECOMMENDED FOR FUNDING,  
21 ONE OF WHICH YOU APPROVED AT THE LAST BOARD MEETING  
22 AND ONE OF WHICH HAS NOT YET BEEN ACTED ON, BUT  
23 BECAUSE IT IS RECOMMENDED BY THE GRANTS WORKING  
24 GROUP, CURRENTLY I TREAT IT AS AWARDED. THAT'S ALSO  
25 BEEN DEDUCTED FROM THE CONCEPT APPROVED.

## BARRISTERS' REPORTING SERVICE

1 THE OTHER KEY CHANGE WAS THE EARLY  
2 TRANSLATIONAL PROGRAM. THE AWARDED FIGURE NOW  
3 INCLUDES THE 69.3 MILLION THAT THIS BOARD FUNDED AT  
4 THEIR MAY MEETING, AND THAT HAS BEEN DEDUCTED FROM  
5 CONCEPT APPROVED BECAUSE FUTURE AWARDS UNALLOCATED  
6 NOW INCLUDES THE BALANCE OF THE 95 MILLION THAT WAS  
7 ORIGINALLY CONCEPT APPROVED FOR THE ET 3. SO THAT'S  
8 ROUGHLY \$25 MILLION.

9 WHAT I HAVE DONE IS I HAVE SUBTRACTED 70  
10 MILLION FROM THE FUTURE AWARDS TRANSLATIONAL  
11 CATEGORY AND ADDED IT TO THE CONCEPT APPROVED IN  
12 HOPEFUL ANTICIPATION OF APPROVAL OF WHAT WE'RE GOING  
13 TO REQUEST AT THIS MEETING, BUT THOSE ARE THE KEY  
14 CHANGES.

15 AND SO IF YOU LOOK AT THE NEXT SLIDE,  
16 SLIDE 3, BASICALLY THIS IS NOW YOUR CURRENT SNAPSHOT  
17 IN TIME, AND THE TABLE BELOW IT ALSO SHOWS THAT. SO  
18 THE FIRST COLUMN -- SORRY -- THE FOURTH COLUMN IN  
19 THE TABLE IS WHAT IS NOW GRAPHED IN THE LEFT-HAND  
20 GRAPH AND THE LAST COLUMN IN THE TABLE IS WHAT IS  
21 NOW GRAPHED IN THE RIGHT-HAND GRAPH. OKAY. SO THIS  
22 JUST GIVES YOU A SENSE OF THE DISTRIBUTION OF THE  
23 MONEY THAT'S ALREADY BEEN FUNDED THAT YOU'VE ALREADY  
24 AWARDED. IT GIVES YOU THE DISTRIBUTION AMONGST THE  
25 CATEGORIES OF THE MONEY THAT YOU HAVE CONCEPT

**BARRISTERS' REPORTING SERVICE**

1 APPROVED.

2 AND ON THE NEXT SLIDE, SLIDE 4, YOU RECALL  
3 WHEN I DISCUSSED THIS WITH YOU AT THE MARCH BOARD  
4 MEETING, I NOTED THAT SORT OF OUR STRATEGIC FUNDING  
5 PROPOSAL FOR FUTURE FUNDING REPRESENTED A SNAPSHOT  
6 IN TIME. SO THE SNAPSHOT HERE HAS BEEN BASICALLY  
7 ADJUSTED SO YOU SEE FUTURE 1, 0812 IS GRAPHED ON THE  
8 LEFT AND FUTURE NO. 2, 0812 IS GRAPHED ON THE RIGHT.  
9 THOSE WERE TWO SCENARIOS. BUT WHAT YOU WILL NOTE IS  
10 THE PRESENCE NOW OF A 115 MILLION IN UNALLOCATED,  
11 WHICH INCLUDES THE CURRENT 25 MILLION NOT AWARDED  
12 FROM THE ET 3 CONCEPT AND THE 89 MILLION AT LEAST TO  
13 DATE THAT HAS NOT BEEN AWARDED FROM THE DT 2 OR THE  
14 DT2D.

15 AND I JUST WANT TO BRING TO YOUR ATTENTION  
16 THAT THAT ACTUALLY UNALLOCATED IS VERY COMPARABLE IN  
17 SIZE TO ALMOST ALL THE OTHER CATEGORIES EXCEPT THE  
18 CATEGORY THAT'S BEEN ALLOCATED TO DEVELOPMENT. SO  
19 THAT JUST GIVES YOU A SENSE OF WHERE WE ARE NOW WITH  
20 THE MONEY THAT IS AVAILABLE FOR OUR FUNDING  
21 STRATEGY.

22 AND THE KEY MESSAGES I JUST WANT YOU TO  
23 TAKE FORWARD, THIS IS SUMMARIZED ON THE LAST SLIDE,  
24 THAT ET 4, ACTUALLY THE 70 MILLION THAT IS GOING TO  
25 BE PROPOSED FOR THE ET WAS ACTUALLY THE AMOUNT THAT



**BARRISTERS' REPORTING SERVICE**

1 WAS CONTEMPLATED BY OUR FUNDING STRATEGY. SO WE  
2 ARE, IN FACT, IMPLEMENTING OUR FUNDING STRATEGY THAT  
3 WAS APPROVED BY THIS BOARD AS PART OF THE STRATEGIC  
4 PLAN. AND I'VE ALREADY SUMMARIZED THAT THE  
5 CURRENTLY UNALLOCATED FUNDS COULD BE AVAILABLE FOR  
6 FUTURE ALLOCATION IF, IN FACT, MORE IS NOT AWARDED.  
7 AND THAT THIS UNALLOCATED POOL IS COMPARABLE IN SIZE  
8 TO MANY OF THE FUTURE FUNDING CATEGORY ALLOCATIONS.

9 SO ARE THERE ANY QUESTIONS? WHAT WE'RE  
10 PUTTING FORWARD IS THIS NEW -- THIS CURRENT  
11 PRESENTATION TO YOU THAT FORMS THE BASE POINT NOW  
12 FOR THE NEXT DISCUSSION AT THE NEXT CONCEPT, SO YOU  
13 CAN KEEP SEEING HOW IT EVOLVES.

14 MS. FEIT: THIS IS MARCY FEIT. I'M ON THE  
15 PHONE. I DIDN'T KNOW IF YOU TOOK ROLL CALL OR NOT.

16 MS. BONNEVILLE: THANK YOU, MARCY.

17 DR. PIZZO: AND PHIL PIZZO IS ON AS WELL.

18 MS. SAMUELSON: WHAT ASSESSMENTS HAVE YOU  
19 DONE? IN OTHER WORDS, WHAT CAN WE KNOW ABOUT WHAT  
20 ADVANCES HAVE BEEN PURCHASED, IF WE CAN BE SO  
21 CONCRETE ABOUT IT, WITH THE MONEY WE'VE SPENT SO  
22 FAR?

23 DR. OLSON: ON WHAT?

24 MS. SAMUELSON: ON MEASURABLE STEPS TOWARD  
25 THERAPIES.

**BARRISTERS' REPORTING SERVICE**

1 DR. OLSON: ARE WE TALKING ABOUT THE EARLY  
2 TRANSLATIONAL PROGRAM PER SE, OR ARE WE TALKING  
3 ABOUT --

4 MS. SAMUELSON: I'M TALKING ABOUT ALL THE  
5 TRANSLATIONAL CATEGORIES WE'RE TALKING ABOUT TODAY,  
6 THE EARLY TRANSLATIONAL THROUGH DISEASE TEAMS.

7 DR. OLSON: WE'RE ONLY REALLY TALKING  
8 ABOUT AN EARLY TRANSLATIONAL -- A CONCEPT PROPOSAL  
9 FOR AN EARLY TRANSLATIONAL --

10 MS. SAMUELSON: I UNDERSTAND. BUT MY  
11 QUESTION IS WHAT CAN BE KNOWN ABOUT WHAT WE BOUGHT  
12 WITH THE MONEY IF WE COULD BE SO SIMPLISTIC ABOUT  
13 IT?

14 DR. OLSON: OKAY. I KNOW THAT DR. FEIGAL,  
15 I BELIEVE, AT THE JANUARY BOARD MEETING PRESENTED  
16 SORT OF -- SORRY -- AT THE MARCH BOARD MEETING  
17 PRESENTED A CURRENT STATUS ON THE DISEASE TEAM  
18 PROGRAMS, AND WE WILL CONTINUE TO UPDATE YOU ON  
19 THOSE AS WE GO FORWARD.

20 WITH REGARD TO THE EARLY TRANSLATIONAL  
21 PROGRAM, THE VERY FIRST EARLY TRANSLATIONAL PROGRAM  
22 THAT HAS BEEN FUNDED BY THIS BOARD WILL JUST BE  
23 ENDING -- IT'S ACTUALLY JUST STARTING TO END NOW.  
24 SO IT WILL BE ENDING FROM NOW THROUGH THE END OF  
25 THIS YEAR. SO IT'S A BIT PREMATURE. THE OTHERS ARE

**BARRISTERS' REPORTING SERVICE**

1 OBVIOUSLY ET 2, WE'RE ONLY NOT EVEN -- MAYBE ABOUT  
2 HALFWAY THROUGH IT. AND THE ET 3 WE'RE JUST NOW  
3 LAUNCHING. SO WE DON'T HAVE A LOT OF OUTCOMES.

4 WHAT I CAN SAY ABOUT THE -- AND SOME OF  
5 THIS WAS CAPTURED IN THE UPDATE TO THE STRATEGIC  
6 GOALS THAT WAS ALSO PRESENTED AS PART OF THE  
7 STRATEGIC PLAN, BUT WHAT WE CAN SAY IS THAT ET 1 HAS  
8 HAD 45 PUBLICATIONS FROM ET 1, THERE HAVE BEEN  
9 (UNINTELLIGIBLE) DISCLOSURES AT 2011. SO THAT'S NOT  
10 UPDATED THROUGH THIS YEAR. THERE HAVE BEEN  
11 CONTRIBUTIONS ACTUALLY TO A NUMBER OF THE DISEASE  
12 TEAM THERAPY DEVELOPMENT PROGRAMS THAT HAVE BEEN  
13 UNDER CONSIDERATION BY THIS BOARD. WE KNOW THAT ONE  
14 OF THEM IS SUPPORTING IND-ENABLING WORK OF A CURRENT  
15 DISEASE TEAM PROGRAM. SO IT WAS ACTUALLY ADDRESSING  
16 DEVELOPING AN ASSAY FOR TUMORGENICITY AND FOR SAFETY  
17 THAT IS ACTUALLY NOW BEING IN FALL. I THINK THERE  
18 ARE ROUGHLY 11 -- THERE ARE ROUGHLY 16 PROGRAMS. I  
19 THINK FOR THE OUTCOMES TO DATE THAT HAVE BEEN  
20 PRELIMINARY, BUT IT'S BEEN LOOKING VERY PROMISING,  
21 AND WHAT WE WOULD HOPE TO DO AT SOME POINT WHEN THE  
22 PROGRAM IS MORE COMPLETE IS ACTUALLY REPORT ON THE  
23 OUTCOMES TO THE BOARD.

24 MS. SAMUELSON: THAT WOULD BE GREAT.  
25 THANK YOU.

## BARRISTERS' REPORTING SERVICE

1 MR. SHESTACK: I JUST HAVE A QUESTION.  
2 THIS IS TRANSLATIONAL IV, RIGHT?

3 DR. OLSON: THAT'S CORRECT.

4 MR. SHESTACK: AND HOW DIFFERENT IS THE  
5 STRUCTURE OF IT THAN TWO OR THREE? IS IT THE SAME?

6 DR. OLSON: WOULD IT BE USEFUL TO -- I  
7 THINK IT'S SIMILAR, BUT THAT IS WHAT DR. COLLINS WAS  
8 GOING TO HIGHLIGHT IN THE CONCEPT PROPOSAL.

9 MR. SHESTACK: OKAY. BECAUSE IN LOOKING  
10 AT THE SLIDES, I COULDN'T REALLY DETERMINE WHAT THE  
11 DIFFERENCES WERE PARTICULARLY BETWEEN THIS ONE AND  
12 PREVIOUS ONES.

13 DR. OLSON: THEY DEFINITELY HAVE SOME  
14 SIMILARITIES IN STRUCTURE. WE ARE FINDING THAT THE  
15 MIX OF PROGRAMS TARGETING A DEVELOPMENT CANDIDATE  
16 FOR APPLICATIONS WHO WANT TO TAKE THAT ROUTE AND THE  
17 MIX OF WHAT WE CALL FEASIBILITY AWARDS FOR  
18 APPLICANTS WHO REALLY JUST WANT TO ASK A VERY  
19 FOCUSED QUESTION, HYPOTHESIS-DRIVEN QUESTION, IS A  
20 GOOD MIX BECAUSE THEN WE MIGHT EXPECT TO SEE SOME OF  
21 THOSE DEVELOPMENT CANDIDATE FEASIBILITY AWARDS BEING  
22 CARRIED FORWARD. SO WE'VE FOUND THIS IS A VERY  
23 POPULAR MIX WITH OUR APPLICANTS.

24 MR. SHESTACK: OKAY. THANK YOU.

25 DR. OLSON: SO ARE THERE ANY FURTHER

## BARRISTERS' REPORTING SERVICE

1 QUESTIONS? IF NOT, I'M GOING TO TURN THE MICROPHONE  
2 NOW OVER TO DR. LILA COLLINS.

3 DR. COLLINS: HOPEFULLY I'M GOING TO  
4 ANSWER SOME OF THOSE QUESTIONS AS WELL. I ASSUME  
5 THAT MOST OF YOU ARE FOLLOWING ALONG ON PAPER. SO  
6 I'M JUST GOING TO GO THROUGH A HARD COPY AS WELL.

7 TODAY, MR. CHAIRMAN AND MEMBERS OF THE  
8 BOARD, THIS AFTERNOON I'D LIKE TO PRESENT TO YOU AND  
9 REQUEST YOUR APPROVAL FOR THE CONCEPT PROPOSAL FOR  
10 THE FOURTH CALL OF OUR EARLY TRANSLATIONAL RFA, AND  
11 I'LL CALL IT ET 4.

12 AS MOST OF YOU ARE ALREADY FAMILIAR WITH  
13 THIS RFA, AS WE JUST DISCUSSED, THE CONCEPT FOR THIS  
14 CALL IS QUITE SIMILAR TO OUR PREVIOUS CALLS WITH  
15 SOME ENHANCEMENTS. SO THIS SHOULD BE A FAMILIAR  
16 DISCUSSION FOR US.

17 THE EARLY TRANSLATIONAL PROGRAM ENABLES  
18 EARLY DEVELOPMENT OF POTENTIALLY TRANSFORMATIVE  
19 THERAPIES. THIS RFA TARGETS FOUR OF OUR STRATEGIC  
20 GOALS AND TO USE THE RFA TO FUND POTENTIALLY HIGH  
21 IMPACT TRANSFORMATIVE PROJECTS TO SUPPORT OUR  
22 BROADER OBJECTIVE OF ACHIEVING TRANSFORMATIVE  
23 RESEARCH. AND THIS IS REALLY THE KEY ENHANCEMENT  
24 FOR THIS CALL, AND I'LL DEFINE AND DISCUSS A BIT  
25 MORE HOW WE PLAN TO IMPLEMENT THIS WITH ET 4 WHEN WE

**BARRISTERS' REPORTING SERVICE**

1 GET TO THE RFA PRIORITIES.

2 IN ADDITION, AS PART OF THE EARLY  
3 TRANSLATIONAL PROCESS, OUR GRANTEES WILL PROVIDE  
4 REPRODUCIBLE DEMONSTRATION OF DISEASE-MODIFYING  
5 ACTIVITY IN RELEVANT MODELS AND DISEASE-SPECIFIC  
6 LINES WILL BE GENERATED. AND FINALLY, WE ANTICIPATE  
7 THAT SOME OF THESE AWARDS WILL IMPACT THE PRODUCTION  
8 OF CRITICAL CELL POPULATIONS.

9 AS YOU CAN SEE FROM THIS PIPELINE OF ALL  
10 OF OUR RFA'S IN THE THIRD SLIDE, THIS RFA WILL  
11 TRANSLATE BASIC STEM CELL DISCOVERIES UP TO THE CELL  
12 (UNINTELLIGIBLE) STAGE. AND THIS IS A POTENTIAL  
13 THERAPY (INAUDIBLE) DEVELOPMENT SUCH AS THAT FUNDED  
14 IN OUR DISEASE TEAM THERAPY DEVELOPMENT GRANTS THAT  
15 WE PASSED AT OUR MEETING LAST MONTH.

16 IN THE NEXT SLIDE, AS WE'VE DISCUSSED, FOR  
17 THE PAST TWO CALLS OF THIS RFA, AS JUST MENTIONED,  
18 WE'VE PROPOSED TWO TYPES OF AWARDS: DEVELOPMENT  
19 CANDIDATE OR DC AND DEVELOPMENT CANDIDATE  
20 FEASIBILITY AWARD, DCF AWARD. NOW, THE DCF AWARDS  
21 WILL ADVANCE DISCOVERIES THROUGH PRECLINICAL PROOF  
22 OF CONCEPT FOR A POTENTIAL APPROACH. SO, FOR  
23 EXAMPLE, AN INVESTIGATOR MAY HAVE IDENTIFIED A NOVEL  
24 POTENTIALLY EXCITING REGENERATIVE APPROACH AND  
25 REALLY WANTS TO TEST IT OUT. THIS WOULD BE AN

## BARRISTERS' REPORTING SERVICE

1 APPROPRIATE USE FOR OUR DCF AWARDS WHILE A DC AWARD  
2 WILL ADVANCE A THERAPEUTIC CANDIDATE TO A MORE  
3 MATURE STATE WHERE THEY COULD BEGIN IND-ENABLING  
4 STUDIES. SO THESE AWARDS WE EXPECT MORE MATURE  
5 OUTCOMES INCLUDING USABLE DEMONSTRATION OF  
6 DISEASE-MODIFYING ACTIVITY IN RELEVANT MODELS, A  
7 MORE COMPLETE SET OF CANDIDATE CHARACTERIZATION  
8 ASSAYS, AS WELL AS PROCESS DEVELOPMENT AND SCALE-UP  
9 ACTIVITIES.

10 SO IN THE NEXT SLIDE, IN ALIGNMENT WITH  
11 CIRM'S MISSION, THESE PROJECTS MUST MEET ONE OF  
12 THREE CRITERIA. THEY ARE REQUIRED TO BE HUMAN STEM  
13 CELLS, TARGET ENDOGENOUS HUMAN STEM CELLS, OR  
14 PROPOSE A DIRECT REPROGRAMMING THERAPEUTIC APPROACH.

15 I'D LIKE TO MENTION THAT CIRM RECENTLY  
16 HOSTED A TISSUE ENGINEERING WORKSHOP, AND WE HAD A  
17 SESSION REALLY DISCUSSING OPPORTUNITIES FOR CIRM TO  
18 MOVE THOSE (INAUDIBLE) FORWARD. AND ONE OF THE KEY  
19 RECOMMENDATIONS THAT CAME OUT OF THAT DISCUSSION WAS  
20 THAT CIRM IS REALLY IN A GREAT POSITION TO FOSTER  
21 THE DEVELOPMENT OF TRANSFORMATIVE REGENERATIVE  
22 APPROACHES. AND THIS ALSO ALIGNS WELL WITH OUR  
23 REVISED STRATEGIC PLAN. SO WE'D LIKE TO SEEK THE  
24 OPPORTUNITY IN THIS RFA TO PRIORITIZE PROGRAMS,  
25 PARTICULARLY THOSE DCF PROPOSALS, THAT PLAN TO

## BARRISTERS' REPORTING SERVICE

1 ESTABLISH PROOF OF CONCEPT FOR POTENTIALLY  
2 TRANSFORMATIVE THERAPEUTIC APPROACHES. BY THAT I  
3 MEAN RATHER THAN AN INCREMENTAL ADVANCE, THESE ARE  
4 POTENTIALLY HIGH IMPACT AND PARADIGM SHIFTING NEW  
5 OPPORTUNITIES TO REGENERATIVE MEDICINE. AND  
6 EXAMPLES MIGHT BE IN VIVO REPROGRAMMING OR TISSUE  
7 ENGINEERING APPROACHES. THOSE WOULD FALL INTO THIS  
8 CATEGORY.

9 IN THE NEXT SLIDE, AS WE HAVE IN THE PAST  
10 THREE CALLS, WE'RE PROPOSING INCLUSION OF CO-PI'S  
11 AND PARTNER PI'S FOR THESE AWARDS. AND I'D ALSO  
12 LIKE TO HIGHLIGHT THAT CIRM DOES ENCOURAGE  
13 PARTNERSHIPS BETWEEN FOR-PROFIT AND NON-PROFIT  
14 INSTITUTIONS, AND THAT PHARMA HAS ACTUALLY INDICATED  
15 AN INTEREST IN FUNDING SOME OF THESE PROJECTS. AND  
16 WE'RE EXCITED ABOUT THAT. AND WE PLAN TO USE OUR  
17 PREAPPLICATION PROCESS IN LIEU OF INSTITUTIONAL  
18 LIMITS AS WE HAVE IN THE PAST THREE CALLS -- TWO  
19 CALLS. AND TODAY WE HAVE ACTUALLY FIVE  
20 COLLABORATIVE FUNDING PARTNERS FOR THIS RFA. SO A  
21 NUMBER OF COLLABORATIVE FUNDING PARTNERS INCLUDING  
22 THE NIH, AUSTRALIA, CHINA, GERMANY, AND INDIA, AND  
23 HOPEFULLY ARGENTINA.

24 LOOKING ONTO THE NEXT SLIDE, WE'RE  
25 PROPOSING A \$70 MILLION FUNDING LEVEL FOR THIS



## BARRISTERS' REPORTING SERVICE

1 PROGRAM, AS DR. OLSON JUST DISCUSSED. THIS IS IN  
2 ALIGNMENT WITH THE SPENDING FOR THE PAST THREE CALLS  
3 WHERE YOU HAVE APPROVED BETWEEN 68 AND \$72 MILLION  
4 IN FUNDING, AND IT'S ALSO IN ALIGNMENT WITH WHAT PAT  
5 JUST DISCUSSED, OUR RFA FUNDING PLAN. WE'LL OFFER  
6 ALSO A LOAN OPTION FOR FOR-PROFIT APPLICANTS FOR  
7 AWARDS OF \$3 MILLION.

8 AND THE NEXT SLIDE PRESENTS OUR TENTATIVE  
9 TIMETABLE FOR THE AWARD. AND WE PLAN TO COME BACK  
10 TO YOU IN THE FALL OF 2013 WITH GRANTS WORKING  
11 GROUP (INAUDIBLE).

12 SO FINALLY, AT THIS TIME I'D LIKE TO  
13 REQUEST YOUR APPROVAL FOR THE RFA CONCEPT, AND THANK  
14 YOU FOR YOUR ATTENTION.

15 CHAIRMAN THOMAS: THANK YOU, PAT AND LILA.  
16 ARE THERE ANY QUESTIONS FROM MEMBERS OF THE BOARD ON  
17 THIS PRESENTATION? HEARING NONE, ARE THERE ANY  
18 COMMENTS FROM MEMBERS OF THE PUBLIC? AND DO I HEAR  
19 A MOTION THAT WE APPROVE THIS CONCEPT APPROVAL?

20 MR. TORRES: SO MOVED.

21 CHAIRMAN THOMAS: MOVED BY SENATOR TORRES.

22 DR. PRIETO: SECOND.

23 CHAIRMAN THOMAS: SECOND AND THAT WAS?

24 DR. PRIETO: FRANCISCO PRIETO.

25 CHAIRMAN THOMAS: THANK YOU, FRANCISCO.

**BARRISTERS' REPORTING SERVICE**

1 IT'S BEEN MOVED AND SECONDED. ANY FURTHER  
2 DISCUSSION? IF NOT, MARIA, WILL YOU PLEASE CALL THE  
3 ROLL.

4 MS. BONNEVILLE: ROBERT PRICE.

5 DR. PRICE: YES.

6 MS. BONNEVILLE: GARY FIRESTEIN. JACOB  
7 LEVIN.

8 DR. LEVIN: YES.

9 MS. BONNEVILLE: CLAIRE POMEROY.

10 DR. POMEROY: YES.

11 MS. BONNEVILLE: MARCY FEIT.

12 MS. FEIT: YES.

13 MS. BONNEVILLE: TED Krontiris.

14 DR. Krontiris: YES.

15 MS. BONNEVILLE: LEEZA GIBBONS.

16 MS. GIBBONS: YES.

17 MS. BONNEVILLE: MICHAEL GOLDBERG.

18 MR. GOLDBERG: YES.

19 MS. BONNEVILLE: SAM HAWGOOD. STEPHEN  
20 JUELsgaard. SHERRY LANSING.

21 MS. LANSING: YES.

22 MS. BONNEVILLE: BERT LUBIN. MICHAEL  
23 MARLETTA. LEON FINE.

24 DR. FINE: YES.

25 MS. BONNEVILLE: PHIL PIZZO.

**BARRISTERS' REPORTING SERVICE**

1 DR. PIZZO: YES.  
2 MS. BONNEVILLE: FRANCISCO PRIETO.  
3 DR. PRIETO: AYE.  
4 MS. BONNEVILLE: CARMEN PULIAFITO. ROBERT  
5 QUINT.  
6 DR. QUINT: YES.  
7 MS. BONNEVILLE: DUANE ROTH.  
8 MR. ROTH: YES.  
9 MS. BONNEVILLE: JOAN SAMUELSON.  
10 MS. SAMUELSON: YES.  
11 MS. BONNEVILLE: DAVID SERRANO-SEWELL.  
12 MR. SERRANO-SEWELL: YES.  
13 MS. BONNEVILLE: JEFF SHEEHY.  
14 MR. SHEEHY: YES.  
15 MS. BONNEVILLE: JONATHAN SHESTACK.  
16 OSWALD STEWARD.  
17 DR. STEWARD: YES.  
18 MS. BONNEVILLE: JONATHAN THOMAS.  
19 CHAIRMAN THOMAS: YES.  
20 MS. BONNEVILLE: ART TORRES.  
21 MR. TORRES: AYE.  
22 MS. BONNEVILLE: KRISTINA VUORI.  
23 DR. VUORI: YES.  
24 MS. BONNEVILLE: JAMES ECONOMOU.  
25 DR. ECONOMOU: YES.

**BARRISTERS' REPORTING SERVICE**

1 CHAIRMAN THOMAS: MOTION PASSES. THANK  
2 YOU VERY MUCH.

3 ON TO THE NEXT ITEM, WHICH IS  
4 CONSIDERATION OF THE APPOINTMENT OF NEW SCIENTIFIC  
5 MEMBERS OF THE GRANTS WORKING GROUP. AND TURN IT  
6 OVER HERE TO DR. SAMBRANO.

7 DR. SAMBRANO: THANK YOU VERY MUCH, CHAIR  
8 AND MEMBERS OF THE BOARD. TODAY WE'RE BRINGING FOR  
9 YOUR CONSIDERATION NINE NOMINEES FOR GRANTS WORKING  
10 GROUP MEMBERS.

11 DR. FIRESTEIN: THIS IS FIRESTEIN. I  
12 COULDN'T UNMUTE MY PHONE. SO I HAD TO HANG UP AND  
13 CALL BACK. SO I VOTED YES.

14 MS. BONNEVILLE: THANK YOU.

15 DR. SAMBRANO: SO THESE ARE MEMBERS THAT  
16 ARE BRINGING KEY SCIENTIFIC EXPERTISE IN AREAS OF  
17 THERAPY DEVELOPMENT, REGULATORY AFFAIRS, GENE  
18 THERAPY, MUSCULOSKELETAL DISEASE, AND EYE DISEASE.  
19 THE BIOS OF THE NOMINEES ARE SHOWN IN THE MATERIALS  
20 THAT WERE SENT TO YOU. AND THE NAMES OF THOSE  
21 NOMINEES ARE JULIA BARRETT, COSIMO DE BARI, MICHEL  
22 SADELAIN, JAVIER SAN MARTIN, BARBARA MATTHEWS,  
23 MAHENDRA RAU, KEITH WELLS, GRANT WILLIAMS, MARCO  
24 ZARBIN.

25 SO WE REQUEST YOUR APPROVAL AND

**BARRISTERS' REPORTING SERVICE**

1 APPOINTMENT OF THESE NOMINEES AS MEMBERS OF THE  
2 GRANTS WORKING GROUP.

3 CHAIRMAN THOMAS: DO I HEAR A MOTION TO  
4 THAT EFFECT?

5 MR. TORRES: SO MOVED.

6 CHAIRMAN THOMAS: MOVED BY SENATOR TORRES.  
7 SECONDED? DO WE HAVE A SECOND?

8 DR. PRIETO: I'LL SECOND.

9 CHAIRMAN THOMAS: THANK YOU, DR. PRIETO.  
10 ANY DISCUSSION BY MEMBERS OF THE BOARD, OR QUESTIONS  
11 OF DR. SAMBRANO ON ANY OF THE PARTICULAR NOMINEES?  
12 HEARING NONE, ANY COMMENTS FROM MEMBERS OF THE  
13 PUBLIC? MARIA, PLEASE TAKE THE ROLL.

14 MS. BONNEVILLE: ROBERT PRICE.

15 DR. PRICE: YES.

16 MS. BONNEVILLE: GARY FIRESTEIN.

17 DR. FIRESTEIN: YES.

18 MS. BONNEVILLE: JACOB LEVIN.

19 DR. LEVIN: YES.

20 MS. BONNEVILLE: CLAIRE POMEROY.

21 DR. POMEROY: YES.

22 MS. BONNEVILLE: MARCY FEIT. TED  
23 Krontiris.

24 DR. Krontiris: YES.

25 MS. BONNEVILLE: LEEZA GIBBONS.

**BARRISTERS' REPORTING SERVICE**

1 MS. GIBBONS: YES.  
2 MS. BONNEVILLE: MICHAEL GOLDBERG.  
3 MR. GOLDBERG: YES.  
4 MS. BONNEVILLE: SAM HAWGOOD. STEPHEN  
5 JUELSGAARD. SHERRY LANSING.  
6 MS. LANSING: YES.  
7 MS. BONNEVILLE: BERT LUBIN. MICHAEL  
8 MARLETTA. LEON FINE.  
9 DR. FINE: YES.  
10 MS. BONNEVILLE: PHIL PIZZO.  
11 DR. PIZZO: YES.  
12 MS. BONNEVILLE: FRANCISCO PRIETO.  
13 DR. PRIETO: AYE.  
14 MS. BONNEVILLE: CARMEN PULIAFITO. ROBERT  
15 QUINT.  
16 DR. QUINT: YES.  
17 MS. BONNEVILLE: DUANE ROTH.  
18 MR. ROTH: YES.  
19 MS. BONNEVILLE: JOAN SAMUELSON.  
20 MS. SAMUELSON: ABSTAIN.  
21 MS. BONNEVILLE: DAVID SERRANO-SEWELL.  
22 MR. SERRANO-SEWELL: YES.  
23 MS. BONNEVILLE: JEFF SHEEHY.  
24 MR. SHEEHY: YES.  
25 MS. BONNEVILLE: JONATHAN SHESTACK.

**BARRISTERS' REPORTING SERVICE**

1 OSWALD STEWARD.

2 DR. STEWARD: YES.

3 MS. BONNEVILLE: JONATHAN THOMAS.

4 CHAIRMAN THOMAS: YES.

5 MS. BONNEVILLE: ART TORRES.

6 MR. TORRES: AYE.

7 MS. BONNEVILLE: KRISTINA VUORI.

8 DR. VUORI: YES.

9 MS. BONNEVILLE: JAMES ECONOMOU.

10 DR. ECONOMOU: YES.

11 MS. FEIT: MARCY FEIT SAYS YES.

12 CHAIRMAN THOMAS: THANK YOU, MARCY. THE  
13 MOTION PASSES. THANK YOU, DR. SAMBRANO, FOR YOUR  
14 CONTINUED EFFORTS TO EVEN FURTHER BOLSTER WHAT IS A  
15 REMARKABLE AND TALENTED POOL OF SCIENTISTS WHO HELP  
16 US IN OUR PEER REVIEW PROCESS. THANK YOU.

17 THAT CONCLUDES TODAY'S ORDER OF BUSINESS.  
18 I WANT TO THANK EVERYBODY FOR TAKING TIME OUT OF  
19 THEIR BUSY AUGUST SCHEDULE TO BE AVAILABLE FOR THIS  
20 CALL. IT WAS VERY IMPORTANT THAT WE WERE ABLE TO  
21 ADDRESS THESE TWO ITEMS IN A TIMELY MANNER. AND IF  
22 I HEAR NO OTHER COMMENTS, I WILL ENTERTAIN A MOTION  
23 WE ADJOURN. SENATOR TORRES.

24 MR. TORRES: SO MOVED.

25 MS. SAMUELSON: SECOND.

**BARRISTERS' REPORTING SERVICE**

1                   CHAIRMAN THOMAS: NUMEROUS SECONDS TO THAT  
2                   EFFECT. THANK YOU VERY MUCH, AND WE LOOK FORWARD TO  
3                   SEEING EVERYBODY AT OUR NEXT REGULARLY SCHEDULED  
4                   MEETING OF THE ICOC WHICH WILL BE ON SEPTEMBER 5TH,  
5                   AND 6TH. EVERYBODY HAVE A NICE END OF SUMMER UP  
6                   UNTIL THEN, AND WE WILL SEE YOU THEN. THANK YOU  
7                   VERY MUCH.

8    (THE MEETING WAS THEN CONCLUDED AT  
9                   4:30 P.M.)

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25



**BARRISTERS' REPORTING SERVICE**

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS SPECIAL MEETING HELD ON TUESDAY, AUGUST 21, 2012, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152  
BARRISTER'S REPORTING SERVICE  
160 S. OLD SPRINGS ROAD  
SUITE 270  
ANAHEIM, CALIFORNIA  
(714) 444-4100